Skip to main content
. 2021 Sep 6;9(25):7417–7432. doi: 10.12998/wjcc.v9.i25.7417

Table 5.

Comparison of the change in visual analogue scale and irritable bowel syndrome symptom severity scale scores in both groups before and after treatment

Parameters
Total, n = 85
Group 1, n = 43
Group 2, n = 42
P value
VAS [Median (min-max)] -50.0 [(-100.0)-40.0] -50.0 [(-100.0)-0.0] -58.3 [(-100.0)-40.0] 0.778
IBS-SSS[Median (min-max)] -47.3 [(-100.0)-30.3)] -43.5 [(-93.0)-0.0)] -50.0 [(-100.0)-30.3) 0.871
Pain severity -50.0 [(-100.0)-50.0] -50.0 [(-100.0)-0.0] -50.0 [(-100.0)-50.0] 0.799
Abdominal pain severity -50.0 [(-100.0)-50.0] -50.0 [(-100.0)-0.0] -50.0 [(-100.0)-50.0] 0.857
Abdominal distention severity -50.0 [(-100.0)-0.0] -50.0 [(-100.0)-0.0] -50.0 [(-100.0)-0.0] 0.561
Satisfaction with intestinal habits -50.0 [(-100.0)-203.0] -50.0 [(-100.0)-100.0] -50.0 [(-100.0)-203.0] 0.953
IBS quality of life -50.0 [(-100.0)-51.5] -50.0 [(-100.0)-0.0] -50.0 [(-100.0)-51.5] 0.960

Group 1: Low fermentable oligo, di- and monosaccharides and polyols (FODMAP) diet + probiotic, Group 2: low fermentable oligo, di- and monosaccharides and polyols diet + placebo. VAS: Visual analogue scale; IBS-SSS: Irritable bowel syndrome symptom severity scale; IBS: Irritable bowel syndrome.